John Erb joined Sunshine Heart as Chief Executive Officer in March 2016 following three months as Interim-CEO. Mr. Erb will continue serving as Sunshine Heart’s Chairman of the Board a position he was appointed to in October of 2012. Mr. Erb has over 40 years of experience in the medical device industry, executive leadership, and financial management. Mr. Erb is also co-founder of NuAx, Inc. (formerly Cardia Access, Inc.), a medical device company involved in developing new devices for the treatment of heart disease.
From 2001 through 2006, Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001, Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica.
Previously, Mr. Erb was Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc. Mr. Erb spent 10 years with Johnson & Johnson’s Iolab Division and started his career with American Hospital Supply Corporation.
Mr. Erb serves as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company and Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb previously served on the Board of Directors of CryoCath Technologies, acquired by Medtronic in 2008 and SenoRx, Inc., acquired by CR Bard in 2010.
Mr. Erb has a bachelor’s degree in business administration from California State University, Fullerton.
Megan Brandt joined Sunshine Heart in August of 2016 as Vice President of Regulatory Affairs and Quality Assurance. Prior to joining Sunshine Heart, Brandt served as Vice President of Quality and Regulatory Affairs at Cardiovascular Systems, Inc. (CSI), a company focused on developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. At CSI, she successfully facilitated numerous domestic and international clinical study submissions and secured multiple regulatory approvals including CE mark, multiple 510(k) clearances, and original PMA approval for their peripheral and coronary orbital atherectomy systems.
She currently serves as Co-Chair for Medical Alley’s Regulatory Advisory Board and is actively involved in multiple FDA working groups including Harmonization by Doing and MDEpiNet’s RAPID programs. In 2014, she was nominated by Minnesota Business Magazine as an Emerging Healthcare Leader. Brandt has held several leadership positions at multiple medical device and pharmaceutical companies including Medafor, Inc., and PDL BioPharma.
Brandt earned her B.S. in Biochemistry and Microbiology from Minnesota State University-Mankato.
Claudia Drayton joined Sunshine Heart in January 2015 as Chief Financial Officer. Ms. Drayton spent the prior 15 years at Medtronic, Inc., a global leader in the medical device industry. During her tenure, she held multiple senior managerial finance positions in Medtronic’s Corporate Finance organization and its Cardiac Rhythm Management division, culminating with a two year assignment in Europe serving as Chief Financial Officer of the Peripheral Vascular Business and most recently, as Chief Financial Officer and Senior Finance Director of the Integrated Health Solutions business. In these capacities her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, business integrations and implementation of financial best practices.
Before Medtronic, Ms. Drayton was an Audit and Business Advisory Manager at Arthur Andersen for seven years. She is a certified public accountant, graduated with a BS in Accounting from the University of Mary Hardin-Baylor and holds an MBA from the University of Minnesota’s Carlson School of Management.
Sandra Eayrs joined Sunshine Heart in 2014 as Director of Human Resources and was appointed to VP of Human Resources in 2015. She is responsible for all aspects of human resources management for the organization and is an advisor to the leadership team in advancing organization capabilities and effectiveness.
Sandra brings more than 20 years of human resources experience in the medical device and other high-tech manufacturing industries. She has held various HR roles with increasing levels of responsibility within Rosemount, Graco, Boston Scientific, and most recently, St. Jude Medical. Additionally, Sandra launched a successful consulting practice utilizing her extensive HR experience and business acumen to consult with multiple clients from small to large Fortune 500 companies in a variety of industries.
Sandra received a Business Administration degree from the University of Wisconsin.
Mr. Lerner has held executive product and organizational development leadership roles at medical diagnostic device firms. Most recently, he was at Senseonics, Inc. as the Vice President of Engineering. Prior to that, he was Chief Technology Officer at Biomedix where he led the company’s development of hardware, software and web-based service solutions for the management of patients with vascular disease. Mr. Lerner was a co-founder and board member of Biomedix and served as the VP of Engineering from 1997 to 2002. During this time, he was instrumental in helping to develop the company’s original product line, including the Portable Vascular Lab, which has evolved into one of the company’s flagship products, PADnet™.
Mr. Lerner has also served as VP of Engineering and Technology for Image Sensing Systems, Inc. and Telex Communications, Inc. where he directed technical activity at multiple domestic and international locations with a strong focus on innovation and on-time delivery. He is the recipient of several device design patents and holds a BS in Electronics Engineering from the State University of New York, as well as an MS in Management and MS in Medical Physics from the University of Minnesota.